177 related articles for article (PubMed ID: 23924802)
41. Congo red populates partially unfolded states of an amyloidogenic protein to enhance aggregation and amyloid fibril formation.
Kim YS; Randolph TW; Manning MC; Stevens FJ; Carpenter JF
J Biol Chem; 2003 Mar; 278(12):10842-50. PubMed ID: 12529361
[TBL] [Abstract][Full Text] [Related]
42. Construction of an scFv library by enzymatic assembly of V(L) and V(H) genes.
Kato M; Hanyu Y
J Immunol Methods; 2013 Oct; 396(1-2):15-22. PubMed ID: 23916870
[TBL] [Abstract][Full Text] [Related]
43. Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment.
Nieba L; Honegger A; Krebber C; Plückthun A
Protein Eng; 1997 Apr; 10(4):435-44. PubMed ID: 9194169
[TBL] [Abstract][Full Text] [Related]
44. Central amyloid-β-specific single chain variable fragment ameliorates Aβ aggregation and neurotoxicity.
Nisbet RM; Nigro J; Breheney K; Caine J; Hattarki MK; Nuttall SD
Protein Eng Des Sel; 2013 Oct; 26(10):571-80. PubMed ID: 23766374
[TBL] [Abstract][Full Text] [Related]
45. Arginine to Lysine Mutations Increase the Aggregation Stability of a Single-Chain Variable Fragment through Unfolded-State Interactions.
Austerberry JI; Thistlethwaite A; Fisher K; Golovanov AP; Pluen A; Esfandiary R; van der Walle CF; Warwicker J; Derrick JP; Curtis R
Biochemistry; 2019 Aug; 58(32):3413-3421. PubMed ID: 31314511
[TBL] [Abstract][Full Text] [Related]
46. Ligation-based assembly for constructing mouse synthetic scFv libraries by chain shuffling with in vivo-amplified VH and VL fragments.
Nishi M; Jian N; Yamamoto K; Seto H; Nishida Y; Tonoyama Y; Shimizu N; Nishi Y
J Immunol Methods; 2014 Oct; 412():53-69. PubMed ID: 25010461
[TBL] [Abstract][Full Text] [Related]
47. Differential effects of apoE and apoJ mimetic peptides on the action of an anti-Aβ scFv in 3xTg-AD mice.
Montoliu-Gaya L; Güell-Bosch J; Esquerda-Canals G; Roda AR; Serra-Mir G; Lope-Piedrafita S; Sánchez-Quesada JL; Villegas S
Biochem Pharmacol; 2018 Sep; 155():380-392. PubMed ID: 30026023
[TBL] [Abstract][Full Text] [Related]
48. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates.
Khurana R; Gillespie JR; Talapatra A; Minert LJ; Ionescu-Zanetti C; Millett I; Fink AL
Biochemistry; 2001 Mar; 40(12):3525-35. PubMed ID: 11297418
[TBL] [Abstract][Full Text] [Related]
49. Improved Brain Expression of Anti-Amyloid β scFv by Complexation of mRNA Including a Secretion Sequence with PEG-based Block Catiomer.
Perche F; Uchida S; Akiba H; Lin CY; Ikegami M; Dirisala A; Nakashima T; Itaka K; Tsumoto K; Kataoka K
Curr Alzheimer Res; 2017; 14(3):295-302. PubMed ID: 27829339
[TBL] [Abstract][Full Text] [Related]
50. Cloning and characterization of cDNAs encoding VH and VL of a monoclonal anti-CEA antibody (CEA 79) cross-reactive with NCA-95 and generation of a single-chain Fv molecule (scFv).
Chung JH; Choi SJ; Kim HJ; Kim IJ; Choi IH; Lee SD; Yi KS; Suh PG; Ryu SH; Chung HK
Mol Cells; 1997 Dec; 7(6):816-9. PubMed ID: 9509426
[TBL] [Abstract][Full Text] [Related]
51. Investigation of the structure of anti-human seminal plasma protein single-chain antibody and its association with linker peptide length.
Jiang X; Zhai J; Song D; Qu Q; Li M; Xing L; Miao S
Mol Med Rep; 2015 Sep; 12(3):4117-4122. PubMed ID: 26099852
[TBL] [Abstract][Full Text] [Related]
52. [Cloning and expression of human single-chain Fv antibody against A beta(1-42) peptide involved in Alzheimer disease].
Jia J; Liu Z; Zhao XM; Liang P
Zhonghua Bing Li Xue Za Zhi; 2008 Jun; 37(6):400-4. PubMed ID: 19031720
[TBL] [Abstract][Full Text] [Related]
53. Progression of Alzheimer's disease and effect of scFv-h3D6 immunotherapy in the 3xTg-AD mouse model: An in vivo longitudinal study using Magnetic Resonance Imaging and Spectroscopy.
Güell-Bosch J; Lope-Piedrafita S; Esquerda-Canals G; Montoliu-Gaya L; Villegas S
NMR Biomed; 2020 May; 33(5):e4263. PubMed ID: 32067292
[TBL] [Abstract][Full Text] [Related]
54. Mutational effects on inclusion body formation in the periplasmic expression of the immunoglobulin VL domain REI.
Chan W; Helms LR; Brooks I; Lee G; Ngola S; McNulty D; Maleeff B; Hensley P; Wetzel R
Fold Des; 1996; 1(2):77-89. PubMed ID: 9079368
[TBL] [Abstract][Full Text] [Related]
55. Rearrangement of the former VL interface in the solution structure of a camelised, single antibody VH domain.
Riechmann L
J Mol Biol; 1996 Jun; 259(5):957-69. PubMed ID: 8683598
[TBL] [Abstract][Full Text] [Related]
56. Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma.
Arndt MA; Krauss J; Schwarzenbacher R; Vu BK; Greene S; Rybak SM
Int J Cancer; 2003 Dec; 107(5):822-9. PubMed ID: 14566834
[TBL] [Abstract][Full Text] [Related]
57. The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain.
Klimtchuk ES; Gursky O; Patel RS; Laporte KL; Connors LH; Skinner M; Seldin DC
Biochemistry; 2010 Nov; 49(45):9848-57. PubMed ID: 20936823
[TBL] [Abstract][Full Text] [Related]
58. VH and VL gene usage by anti-beta-amyloid autoantibodies in Alzheimer's disease: detection of highly mutated V regions in both heavy and light chains.
Fang Q; Kannapell CC; Fu SM; Xu S; Gaskin F
Clin Immunol Immunopathol; 1995 May; 75(2):159-67. PubMed ID: 7704974
[TBL] [Abstract][Full Text] [Related]
59. Cloning of scFv from hybridomas using a rational strategy: Application as a receptor to sensitive detection microcystin-LR in water.
Zhang X; He K; Zhao R; Wang L; Jin Y
Chemosphere; 2016 Oct; 160():230-6. PubMed ID: 27380224
[TBL] [Abstract][Full Text] [Related]
60. Improving the productivity of single-chain Fv antibody against c-Met by rearranging the order of its variable domains.
Kim YJ; Neelamegam R; Heo MA; Edwardraja S; Paik HJ; Lee SG
J Microbiol Biotechnol; 2008 Jun; 18(6):1186-90. PubMed ID: 18600066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
